Skip to main content
Clinical Trials/NCT04937010
NCT04937010
Recruiting
Not Applicable

Efficacy and Safety of Occipital Nerve Stimulation in Trigeminal Autonomic Cephalalgias: A Double-blind, Phase II, Randomized, Controlled Trial

Alberta Health Services, Calgary1 site in 1 country20 target enrollmentFebruary 1, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Trigeminal Autonomic Cephalgia
Sponsor
Alberta Health Services, Calgary
Enrollment
20
Locations
1
Primary Endpoint
Change in headache frequency
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

The objective of this study is to determine the efficacy of occipital nerve stimulation (ONS) in the treatment of chronic trigeminal autonomic cephalalgias (TACs).

Detailed Description

Several open studies and case series have shown improvement in pain scores using ONS specifically for cluster headache, which is the most common of the TACs. However, neuromodulation in the treatment of pain disorders is subject to strong placebo effect and bias, and the lack of controlled studies in this population makes its true efficacy unknown. Therefore, we plan to study ONS in a population of patients with chronic TACs using a double-blind, randomized, controlled, cross-over study. Using sub-threshold stimulation parameters, meaning patients will not know when therapeutic stimulation is active, subjects will rate their pain and quality of life during both therapeutic and sham stimulation periods. Following the cross-over period, all subjects will undergo therapeutic stimulation for 1-year in order to gauge long-term effects.

Registry
clinicaltrials.gov
Start Date
February 1, 2022
End Date
September 1, 2026
Last Updated
last year
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Sponsor
Alberta Health Services, Calgary
Responsible Party
Principal Investigator
Principal Investigator

Fady Girgis

Physician

Alberta Health Services, Calgary

Eligibility Criteria

Inclusion Criteria

  • Meets ICHD-3 diagnostic criteria for the chronic form of one of the trigeminal autonomic cephalgias (outlined below), as determined by the treating neurologist.
  • Failed standard medical management, meaning at least 3 conventional preventative therapies.

Exclusion Criteria

  • Presence of uncontrolled or untreated psychiatric disease
  • Presence of medical contraindications to surgery
  • Patient does not consent to surgery
  • Non-English speaking

Outcomes

Primary Outcomes

Change in headache frequency

Time Frame: 6 months

Change in frequency of headaches

Secondary Outcomes

  • Safety of Occipital Nerve Stimulation(6 months)

Study Sites (1)

Loading locations...

Similar Trials